DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance

MLA

Togami, Katsuhiro, et al. “DNA Methyltransferase Inhibition Overcomes Diphthamide Pathway Deficiencies Underlying CD123-Targeted Treatment Resistance.” Journal of Clinical Investigation, vol. 129, no. 11, Nov. 2019, p. 5005. EBSCOhost, https://doi.org/10.1172/JCI128571.

APA

Togami, K., Pastika, T., Stephansky, J., Ghandi, M., Christie, A. L., Jones, K. L., Johnson, C. A., Lindsay, R. W., Brooks, C. L., Letai, A., Craig, J. W., Pozdnyakova, O., Weinstock, D. M., Montero, J., Aster, J. C., Johannessen, C. M., & Lane, A. A. (2019). DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. Journal of Clinical Investigation, 129(11), 5005. https://doi.org/10.1172/JCI128571

Chicago

Togami, Katsuhiro, Timothy Pastika, Jason Stephansky, Mahmoud Ghandi, Amanda L. Christie, Kristen L. Jones, Carl A. Johnson, et al. 2019. “DNA Methyltransferase Inhibition Overcomes Diphthamide Pathway Deficiencies Underlying CD123-Targeted Treatment Resistance.” Journal of Clinical Investigation 129 (11): 5005. doi:10.1172/JCI128571.